Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor

masaki shiota, Keijiro Kiyoshima, Akira Yokomizo, ario takeuchi, Eiji Kashiwagi, Takashi Dejima, Ryosuke Takahashi, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer. Materials and Methods We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia. Results We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1%) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer. Conclusions Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis.

Original languageEnglish
Pages (from-to)308-313
Number of pages6
JournalJournal of Urology
Volume197
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Urinary Bladder Neoplasms
Androgens
Oxidoreductases
Recurrence
Therapeutics
Muscles
Neoplasms
Prostatic Hyperplasia
Prostatic Neoplasms
Multivariate Analysis
Smoking

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor. / shiota, masaki; Kiyoshima, Keijiro; Yokomizo, Akira; takeuchi, ario; Kashiwagi, Eiji; Dejima, Takashi; Takahashi, Ryosuke; Inokuchi, Junichi; Tatsugami, Katsunori; Eto, Masatoshi.

In: Journal of Urology, Vol. 197, No. 2, 01.02.2017, p. 308-313.

Research output: Contribution to journalArticle

@article{7525f2123072434f8a988300c688feec,
title = "Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor",
abstract = "Purpose We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer. Materials and Methods We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia. Results We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5{\%}) and 59 men (30.1{\%}) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1{\%}) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer. Conclusions Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis.",
author = "masaki shiota and Keijiro Kiyoshima and Akira Yokomizo and ario takeuchi and Eiji Kashiwagi and Takashi Dejima and Ryosuke Takahashi and Junichi Inokuchi and Katsunori Tatsugami and Masatoshi Eto",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.juro.2016.08.006",
language = "English",
volume = "197",
pages = "308--313",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor

AU - shiota, masaki

AU - Kiyoshima, Keijiro

AU - Yokomizo, Akira

AU - takeuchi, ario

AU - Kashiwagi, Eiji

AU - Dejima, Takashi

AU - Takahashi, Ryosuke

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Eto, Masatoshi

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer. Materials and Methods We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia. Results We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1%) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer. Conclusions Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis.

AB - Purpose We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer. Materials and Methods We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia. Results We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1%) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer. Conclusions Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85008154379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008154379&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2016.08.006

DO - 10.1016/j.juro.2016.08.006

M3 - Article

C2 - 27506696

AN - SCOPUS:85008154379

VL - 197

SP - 308

EP - 313

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -